Webinars & Presentations
CGC 2020: Productivity-focused solutions for precision oncology
- Gang Song, Ph.D., Founder and CEO of Pillar Biosciences
- August 5, 2020 at the Cancer Genomics Consortium (CGC) 2020 Meeting
- Dr. Gang Song, Founder and CEO of Pillar Biosciences, succinctly highlights Pillar's accessible precision oncology solutions at the CGC 2020 Virtual Meeting
Finding flexibility in a resource-limited world
- Cynthia Schandl, M.D., Ph.D. and Julie Hirschhorn, Ph.D. of the Medical University of South Carolina
- November 6, 2019
- Drs. Schandl and Hirschhorn discuss their evaluation of the single-tube Stem-Loop Inhibition Mediated Amplification (SLIMamp®) technology from Pillar Biosciences for detection of variants in solid and myeloid tumors.
Making precision medicine accessible with SLIMamp®: robust, rapid, single-tube multiplex NGS panels
- Martin Zillmann, Ph.D., Chief Operating Officer and Vice President of Research and Development at Pillar Biosciences
- March 24, 2019
- Dr. Zillmann presented data demonstrating the performance of Pillar’s key proprietary NGS technologies, including SLIMamp® chemistry, ampPD™ primer design software, and PiVAT® bioinformatics pipeline software. Dr. Zillmann also presented data from de-identified clinical samples demonstrating high sensitivity for the detection of low allele frequency mutations from low DNA inputs.
Rapid testing of solid tumor samples using a single-vial NGS assay
- Paul Waring, Ph.D., Professor of Pathology, University of Melbourne and Scientific Advisory Board member at Pillar Biosciences
- February 19, 2019
- Dr. Waring demonstrates how clinical laboratories can develop their own customized targeted NGS-based solid tumor panels
Strategies for biomarkers to enhance development of novel therapeutics
- Paul Waring, Ph.D., Professor of Pathology, University of Melbourne
- January 22, 2019 at PMWC 2019 Clinical & Research Tools Showcase
- Dr. Waring discusses the current state of precision medicine for oncology and unmet diagnostic needs
Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material
- Helen Fernandes, Ph.D., Co-Director, Genomic Oncology at Columbia University
- October 31, 2018 at AMP 2018 Corporate Workshop Day
- Dr. Fernandes shares their rationale and experience validating a Pillar NGS assay
Dive straight into the feedback!Login below and you can start commenting using your own user instantly